Your browser is no longer supported. Please, upgrade your browser.
Settings
IMNM [NASD]
Immunome, Inc.
Index- P/E- EPS (ttm)-2.00 Insider Own10.90% Shs Outstand11.46M Perf Week22.16%
Market Cap250.63M Forward P/E- EPS next Y-1.86 Insider Trans15.20% Shs Float8.59M Perf Month-9.05%
Income-21.60M PEG- EPS next Q-0.42 Inst Own20.20% Short Float2.47% Perf Quarter38.82%
Sales- P/S- EPS this Y-48.70% Inst Trans-0.93% Short Ratio1.43 Perf Half Y-16.39%
Book/sh5.29 P/B4.27 EPS next Y- ROA-52.90% Target Price36.00 Perf Year80.80%
Cash/sh5.39 P/C4.19 EPS next 5Y- ROE-95.10% 52W Range9.27 - 63.78 Perf YTD133.47%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.57% Beta-
Dividend %- Quick Ratio17.80 Sales past 5Y- Gross Margin- 52W Low143.67% ATR1.60
Employees23 Current Ratio17.80 Sales Q/Q- Oper. Margin- RSI (14)65.68 Volatility9.78% 7.33%
OptionableYes Debt/Eq0.00 EPS Q/Q21.20% Profit Margin- Rel Volume1.66 Prev Close19.38
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume148.83K Price22.60
Recom1.00 SMA2019.64% SMA5021.00% SMA2005.38% Volume249,015 Change16.62%
Oct-20-21 08:00AM  
Oct-18-21 10:01AM  
Oct-07-21 09:00AM  
Sep-30-21 04:35PM  
Sep-22-21 04:05PM  
Sep-15-21 04:05PM  
Sep-13-21 11:49AM  
Sep-07-21 07:00AM  
04:52AM  
Aug-19-21 04:05PM  
02:02PM  
Jul-20-21 08:44AM  
07:00AM  
Jul-06-21 07:00AM  
Jun-30-21 07:00AM  
Jun-17-21 07:00AM  
May-29-21 04:33AM  
May-27-21 04:05PM  
May-20-21 10:04AM  
07:00AM  
May-12-21 06:00AM  
Apr-26-21 08:09AM  
06:00AM  
05:50AM  
Apr-20-21 08:00AM  
04:47AM  
Mar-30-21 08:00AM  
Mar-25-21 05:14PM  
Mar-23-21 07:00AM  
Feb-18-21 07:06PM  
09:21AM  
07:00AM  
05:15AM  
Feb-03-21 07:00AM  
Feb-01-21 07:00AM  
Jan-17-21 03:53AM  
Dec-10-20 08:00AM  
Nov-17-20 05:53PM  
Oct-13-20 04:05PM  
Oct-02-20 05:53PM  
11:23AM  
Oct-01-20 08:23PM  
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RAPP MICHAELDirectorSep 13Buy19.9625,962518,202208,742Sep 14 07:28 AM
RAPP MICHAELDirectorSep 10Buy17.8515,500276,675182,780Sep 13 07:52 AM
RAPP MICHAELDirectorSep 09Buy18.1930,450553,774167,280Sep 13 07:52 AM
BARON RICHARD ADirectorAug 18Option Exercise11.382,34326,6632,343Aug 20 06:25 PM
Lefenfeld MichaelDirectorMay 26Buy19.031,33525,40526,872May 26 09:32 PM
RAPP MICHAELDirectorMay 26Buy18.942,30043,562136,830May 26 09:31 PM
RAPP MICHAELDirectorMay 25Buy18.3219,303353,631134,530May 26 09:31 PM
Lefenfeld MichaelDirectorMay 25Buy18.442,71550,06525,537May 26 09:32 PM
Sarma Purnanand DPresident and CEOMay 25Buy18.4110,500193,30510,500May 26 09:28 PM
LAMATTINA JOHN LDirectorMay 24Buy18.575,440101,02851,828May 26 09:26 PM
Lefenfeld MichaelDirectorMay 24Buy17.8060010,68022,822May 26 09:32 PM
RAPP MICHAELDirectorMay 24Buy18.3831,895586,230115,227May 26 09:31 PM
WAGENHEIM PHILIPDirectorMay 24Buy18.3513,500247,725397,397May 26 09:29 PM